triciribine has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caldwell, RB; Ford, E; Liu, F; Narayanan, SP; Shan, S; Somanath, PR | 1 |
| Cseh, A; Szalay, B; Szebeni, B; Vásárhelyi, B | 1 |
2 other study(ies) available for triciribine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Triciribine attenuates pathological neovascularization and vascular permeability in a mouse model of proliferative retinopathy.
Topics: Animals; Animals, Newborn; Capillary Permeability; Disease Models, Animal; Inflammation; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Oxygen; Retinal Diseases; Retinal Neovascularization; Vascular Endothelial Growth Factor A; Vitreoretinopathy, Proliferative | 2023 |
[Akt enzyme: new therapeutic target in cancer and diabetes?].
Topics: Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Diabetes Mellitus; Enzyme Activation; Humans; Hypoglycemic Agents; Insulin Resistance; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Ribonucleosides | 2009 |